The classical immune checkpoints of PD-1 and PD-L1 of ICIs have achieved significant efficacy in treating many cancers, but most PCa patients are not sensitive to the therapy (Xu et al. 2021; Yi et al. 2022). This evidence concerns the gene CD274 and posterior cortical atrophy.